Citigroup
GTBP icon

Citigroup’s GT Biopharma GTBP Stock Holding History

Citigroup’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-111
Closed -$2.18K – 6123
2025
Q4 		$2.18K Buy
+111
New +$1.97K ﹤0.01% 5443
2022
Q3 		– Hold
0
– -$1K – 6025
2022
Q2 		– Sell
-1
Closed -$1.9K – 6026
2022
Q1 		$2K Sell
1
-5
-83% -$11K ﹤0.01% 6061
2021
Q4 		$14K Buy
6
+3
+100% +$11.2K ﹤0.01% 5488
2021
Q3 		$14K Sell
3
-5
-63% -$37.6K ﹤0.01% 5371
2021
Q2 		$95K Buy
+8
New +$83.1K ﹤0.01% 4530

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
I
INVST Indianapolis, Indiana $1.03B AUM 29.49% 1-Year Est. Return

Citigroup's GTBP Position: Q1 2026 in Review

Citigroup sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 111 shares — an estimated $2.18K sold.

Citigroup first reported a position in GTBP in Q2 2021 and held it in 5 quarters. The position peaked at $95K in Q2 2021. 40 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Citigroup reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 111 GT Biopharma shares in Q1 2026, an estimated $2.18K.
  • Citigroup first reported a position in GT Biopharma in Q2 2021 and held it in 5 quarters.
  • Citigroup's GT Biopharma position peaked at $95K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.